Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 10-2024 | 07-2024 | 04-2024 | 01-2024 | 10-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,390 | -974 | -9,948 | -9,096 | -6,434 |
| Depreciation Amortization | 25 | 13 | 51 | 38 | 25 |
| Other Working Capital | -2,263 | -185 | 671 | 1,341 | 909 |
| Other Operating Activity | 172 | 91 | 956 | 874 | 688 |
| Operating Cash Flow | $-4,456 | $-1,056 | $-8,270 | $-6,843 | $-4,812 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -90 | -90 | -147 | -147 | -147 |
| Investing Cash Flow | $-90 | $-90 | $-147 | $-147 | $-147 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 300 | N/A | N/A |
| Common Stock Issued | 1,174 | N/A | 1,252 | 983 | 18 |
| Other Financing Activity | 7,089 | 1,964 | 2,100 | 1,150 | 0 |
| Financing Cash Flow | $8,263 | $1,964 | $3,652 | $2,133 | $18 |
| Beginning Cash Position | 376 | 376 | 5,141 | 5,141 | 5,141 |
| End Cash Position | 4,093 | 1,194 | 376 | 283 | 200 |
| Net Cash Flow | $3,717 | $818 | $-4,765 | $-4,858 | $-4,941 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,456 | -1,056 | -8,270 | -6,843 | -4,812 |
| Capital Expenditure | -90 | -90 | -147 | -147 | -147 |
| Free Cash Flow | -4,546 | -1,146 | -8,417 | -6,991 | -4,959 |